Psoriasis in France and associated risk factors: results of a case-control study based on a large community survey.
BACKGROUND
Risk factors for psoriasis have been identified.


OBJECTIVE
To precisely define these associated factors.


METHODS
A survey was conducted using a questionnaire on a representative sample of the French population. A case-control study was conducted. Cases were persons who declared having had psoriasis during the previous 12 months. For each case, 3 matched controls were selected. Cases and controls were compared using univariate and multivariate analyses.


RESULTS
The questionnaire was filled out and returned by 6,887 (68.9%) of 10,000 subjects aged 15 years and over; 356 cases were identified. In multivariate analysis, a higher body mass index, current and former smoking habits and beta-blocker intake were independently associated with a higher risk of psoriasis; intake of statins was associated with a decreased risk (p < 0.05).


CONCLUSIONS
We confirmed the association of overweight, smoking habits and beta-blocker intake with psoriasis and reported a decreased risk associated with statin intake.
Wolkenstein
P
P
Department of Dermatology, Albert Chenevier-Henri Mondor, Faculty of Medicine, Paris 12 University, Créteil, France. pierre.wolkenstein@hmn.aphp.fr
Revuz
J
J
Roujeau
J C
JC
Bonnelye
G
G
Grob
J J
JJ
Bastuji-Garin
S
S
D000328:Adult; D017677:Age Distribution; D000368:Aged; D000704:Analysis of Variance; D015992:Body Mass Index; D016022:Case-Control Studies; D005260:Female; D005602:France / Q000453:epidemiology; D006306:Health Surveys; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D050177:Overweight / Q000150:complications*; D011565:Psoriasis / Q000453:epidemiology* / Q000209:etiology* / Q000517:prevention & control; D018570:Risk Assessment; D012307:Risk Factors; D012907:Smoking / Q000009:adverse effects*; D011795:Surveys and Questionnaires
D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors